Cytomegalovirus ventriculoencephalitis in a reduced- intensity conditioning cord blood transplant recipient

Transplant Infectious Disease

Volumn 12, Issue 5, 2010, Pages 441-445

  Ando, T ^a   Mitani, N ^a   Yamashita, K ^a   Takahashi, T ^a   Ohama, E ^b   Miyata, H ^b   Yujiri, T ^a   Tanizawa, Y ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Cord blood; Cytomegalovirus encephalitis; HHV 6 limbic encephalitis; Human herpesvirus 6; Reduced intensity conditioning; Transplantation

Indexed keywords

FLUDARABINE; FOSCARNET; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; STEROID; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; COMMUNICATING HYDROCEPHALUS; CYTOMEGALOVIRUS INFECTION; ENCEPHALITIS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOENCEPHALOPATHY; MULTIFOCAL NECROTIZING LEUKOENCEPHALOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TRANSPLANTATION; UMBILICAL CORD BLOOD; UMBILICAL CORD BLOOD TRANSPLANTATION; VENTRICULOENCEPHALITIS; WHOLE BODY RADIATION;

CEREBRAL VENTRICLES; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS; ENCEPHALITIS, VIRAL; FEMALE; HUMANS; MIDDLE AGED; TRANSPLANTATION CONDITIONING;

EID: 78650444910     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00503.x     Document Type: Article

References (24)

1. Arribas JR, Storch GA, Clifford DB, Tselis AC. Cytomegalovirus encephalitis. Ann Intern Med 1996; 125: 577-587.
2. Miller GG, Boivin G, Dummer JS, et al. Cytomegalovirus ventriculoencephalitis in a peripheral blood stem cell transplant recipient. Clin Infect Dis 2006; 42: e26-e29.
3. Seo SK, Regan A, Cihlar T, et al. Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. Clin Infect Dis 2001; 33: e105-e108.
4. Julin JE, Van Burik JH, Krivit W, et al. Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. Transpl Infect Dis 2002; 4: 201-206.
5. Hamprecht K, Eckle T, Prix L, et al. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis 2003; 187: 139-143.
6. Zeiser R, Grullich C, Berts H, et al. Late cytomegalovirus polyradiculopathy following haploidentical CD34+-selected hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 243-245.
7. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood 1994; 83: 2392-2398.
8. Albano MS, Taylor P, Pass RF, et al. Umbilical cord blood transplantation and cytomegalovirus: posttransplantation infection and donor screening. Blood 2006; 108: 4275-4282.
9. Ogata M. Human herpesvirus 6 in hematological malignancies. J Clin Exp Hematop 2009; 49: 57-67.
10. Serabe BM, Murry DJ, Dauser R, et al. Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. Cancer Chemother Pharmacol 1999; 43: 415-418.
11. Raffi F, Taburet AM, Ghaleh B, Huart A, Singlas E. Penetration of foscarnet into cerebrospinal fluid of AIDS patients. Antimicrob Agents Chemother 1993; 37: 1777-1780.
12. Fletcher C, Sawchuk R, Chinnock B, Demiranda P, Balfour HH Jr. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986; 40: 281-286.
13. Wagstaff AJ, Bryson HM. Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48: 199-226.
14. DesJardin JA, Cho E, Supran S, Gibbons I, Werner BG, Snydman DR. Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients. Clin Infect Dis 2001; 33: 1358-1362.
15. Griffiths PD, Ait-Khaled M, Bearcroft CP, et al. Human herpesvirus 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. J Med Virol 1999; 59: 496-501.
16. Mendez JC, Dockrell DH, Epsy MJ, et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001; 183: 179-184.
17. DesJardin JA, Gibbons L, Cho E, et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 1998; 178: 1783-1786.
18. Singh N. Interactions between viruses in transplant recipients. Clin Infect Dis 2005; 40: 430-436.
19. Lusso P, Malnati M, De Maria A, et al. Productive infection of CD4+ and CD8+ mature human T cell populations and clones by human herpesvirus 6. Transcriptional down-regulation of CD3. J Immunol 1991; 147: 685-691.
20. Yasukawa M, Inoue Y, Ohminami H, Terada K, Fujita S. Apoptosis of CD4+ T lymphocytes in human herpesvirus-6 infection. J Gen Virol 1998; 79: 143-147.
21. Flamand L, Gosselin J, Stefanescu I, Ablashi D, Menezes J. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation. Blood 1995; 85: 1263-1271.
22. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P. CD46 is a cellular receptor for human herpesvirus 6. Cell 1999; 99: 817-827.
23. Lusso P, Malnati MS, Garzino-Demo A, Crowley RW, Long EO, Gallo RC. Infection of natural killer cells by human herpesvirus 6. Nature 1993; 362: 458-462.
24. Lusso P, Markham PD, Tschachler E, et al. In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6). J Exp Med 1988; 167: 1659-1670.